Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sumitomo Pharma America, Inc.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Entry Criteria:
Screening for the present study will take place after subjects' participation in Study D1050233 has been completed, and after providing informed consent.
Completed all required assessments on the final study visit in Study D1050233.
Suitable for treatment in an outpatient setting.
You may not be if
Any chronic organic disease of the CNS (other than schizophrenia).
Considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.
Clareo Health | Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
